SRY-box transcription factor 9 (SOX9)

SRY-box transcription factor 9 (SOX9) is a master regulatory transcription factor belonging to the SOX (SRY-related HMG-box) family, characterized by a highly conserved high-mobility group (HMG) DNA-binding domain. It plays a critical role in embryonic development, particularly as the primary driver of chondrogenesis and a key factor in male sex determination through the regulation of anti-Müllerian hormone (AMH). In adult tissues, SOX9 is essential for maintaining stem cell populations and regulating cell fate in organs such as the liver, pancreas, and intestine. Dysregulation of SOX9 is strongly linked to human disease; heterozygous mutations lead to campomelic dysplasia, a severe skeletal malformation syndrome, while its overexpression is a hallmark of many aggressive cancers where it promotes epithelial-mesenchymal transition (EMT), metastasis, and chemoresistance. In the context of drug development, SOX9 is an emerging therapeutic target for oncology and fibrosis, with research focusing on small molecule inhibitors that disrupt its DNA binding or protein-protein interactions, as well as RNA interference strategies to modulate its expression.

Other names

SOX-9CMD1CMPD1SRA1SRY-related HMG-box gene 9

Inhibition of DNA binding, disruption of protein-protein interactions with co-activators (e.g., MED12, CBP/p300), modulation of upstream signaling pathways (Notch, Wnt, TGF-beta), or RNA interference-mediated knockdown.